Skip to content
Stack & save: 10% off 3+ vials, 15% off 5+ · Free shipping over $250
Cart 0
Compound Files

Retatrutide Research Guide: Three Receptors, One Peptide

Meet the molecule behind Hero RT: a three-receptor research peptide. Explore its scientific background, evidence limits, vial sizes, and laboratory documentation.

Hero Peptides Research TeamUpdated Nov 20265 min read

Quick facts

Compound Retatrutide
Development name LY3437943
Target profile GIP, GLP-1, and glucagon receptor agonism
Hero vial sizes 10 mg, 20 mg, and 30 mg
Evidence distinction Research material is separate from clinical trial preparations
Hero product Hero RT

Retatrutide is an engineered peptide investigated for activity at three metabolic hormone receptors: GIP, GLP-1, and glucagon. That combination makes it an interesting subject for receptor research. The useful starting point is understanding what each target adds to the scientific question, rather than treating three receptors as a score.

Hero RT is the Hero Peptides catalog name for retatrutide research material, listed in 10 mg, 20 mg, and 30 mg vials. This guide explains the molecule behind the name, how to read its evidence, and which material details belong in a laboratory record.

Hero RT. View catalog product

Origin story: from LY3437943 to retatrutide

The discovery program described LY3437943 as a single molecule with activity at the glucagon, GIP, and GLP-1 receptors. Its published work included receptor assays, animal experiments, and early clinical investigation. Retatrutide is the name now associated with that development code (Coskun et al., 2022).

A development code is useful when searching older literature. A paper can discuss LY3437943 without using retatrutide in its title. Searching both names helps connect early pharmacology to later studies while keeping the actual preparation and experimental setting visible.

That continuity does not establish that every commercial research sample is equivalent to the material in those studies. The publication identifies a scientific program. The certificate and analytical results for a particular lot identify the material available for a new experiment.

How retatrutide works: mapping the three targets

An agonist activates a receptor. A triple agonist has a target profile spanning three receptors, but the label does not mean equal activity at all three. The discovery work evaluated receptor responses separately, an important distinction when interpreting a combined pharmacological profile (Coskun et al., 2022).

For a receptor experiment, define the question before choosing a comparison. Are you measuring binding, a downstream signal, or a later cellular response? These measurements can support different conclusions even when the same compound is used.

A concentration-response curve can describe how the measured signal changes across tested concentrations. It cannot, on its own, establish why an organism-level outcome occurs. Receptor expression, incubation time, and the assay readout should accompany the curve.

The single, dual, and triple agonist guide explains the target-count terminology. It is useful background when selecting controls that distinguish one receptor’s contribution from the full molecule’s measured response.

Key studies: read the model before the headline

Evidence Setting Question addressed Important boundary
Discovery program, 2022 Receptor assays, animals, and early clinical work Characterization of the triple-agonist concept Separate experiments answer separate questions
Phase 2 obesity trial, 2023 338 adults; 48 weeks Clinical efficacy and adverse events in a defined population Clinical preparation and supervised trial conditions
Later development Phase 3 program Further clinical evaluation Development status is not product approval

The phase 2 obesity trial reported body-weight changes and adverse events in adults without diabetes. Gastrointestinal events were common, and dose-dependent heart-rate increases were reported. Those findings belong to the study population and preparation, not to a performance claim for Hero RT (Jastreboff et al., 2023).

A practical reading method is to record the population, comparator, duration, endpoint, and analysis beside each result. This prevents a percentage from becoming detached from the question the trial tested. Keep adverse events and discontinuations alongside efficacy outcomes.

Weak spots: what the evidence cannot establish

As of November 17, 2026, retatrutide remains investigational. Lilly’s current development information identifies ongoing clinical research. An investigational status describes development; it does not provide approval for a supplier’s material (Eli Lilly, 2026).

Three-target activity also creates an attribution problem. If an experiment produces a different signal from a single-target comparator, that result alone does not quantify the contribution of each receptor. Appropriate controls are part of the explanation.

Likewise, an identity result and chromatographic purity figure do not establish every property of a sample. They do not independently supply a stability period, a sterility result, or a validated biological potency. Read the scope of the tests actually performed.

Handling retatrutide in the lab

Start with the lot documentation and the solvent requirements of the intended assay. Vial mass and final solution concentration are separate quantities. The 10 mg, 20 mg, and 30 mg options identify different nominal amounts of material; the laboratory preparation determines concentration.

For arithmetic only, nominal 10 mg, 20 mg, and 30 mg amounts brought to a final volume of 2 mL give 5 mg/mL, 10 mg/mL, and 15 mg/mL respectively. Use a suitable laboratory vessel; these hypothetical volumes do not establish the supplied vial capacity. These examples do not select a solvent, prescribe a preparation method, or establish a storage interval.

Record final volume, solvent, preparation date, lot number, and any subsequent dilution. Keep the distinction between a nominal calculation and an analytically measured concentration. Follow the retatrutide laboratory math guide and use the concentration calculator to check the arithmetic.

Hero’s supplied catalog identifies Northfield Analytical as its HPLC and mass-spectrometry testing partner. Match the actual report to the lot before assigning a purity or identity result. The COA guide explains the fields to examine.

Retatrutide FAQ

Is retatrutide the same molecule as tirzepatide?

No. Retatrutide includes glucagon receptor activity in its target profile. Tirzepatide is characterized as a GIP/GLP-1 dual agonist. Receptor count alone does not establish equivalence or superiority.

Does a 30 mg vial have a higher concentration than a 10 mg vial?

Only if both are prepared to the same final volume under comparable conditions. A vial’s nominal mass is not itself a solution concentration.

Is Hero RT the preparation used in Lilly’s clinical trials?

No equivalence is established here. Published trial findings concern the trial preparation, while Hero RT is a separately supplied laboratory material.

What is Hero RT?

Hero RT is Hero Peptides’ retatrutide research material, listed in 10 mg, 20 mg, and 30 mg vials. Consult the linked product and matching lot documentation for the supplied specifications.

Hero RT. View catalog product

References

  1. Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. Source.
  2. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. N Engl J Med. 2023;389:514-526. Source.
  3. Eli Lilly and Company. Clinical Development Pipeline. Current development information, checked November 17, 2026. Source.
For laboratory research use only. Not for human or veterinary use. This article is educational and is not medical advice.

Read next

Add 3 vials for 10% off
Build my stack